Supernus PharmaceuticalsSupernus Pharmaceuticals ( SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. This stock closed up 5.2% to $5.39 on Tuesday. Tuesday's Range: $4.94-$5.44 52-Week Range: $4.30-$16.68 Volume: 1.53 million Three-Month Average Volume: 381,992 Shares of SUPN ripped higher on Tuesday after the company beat Wall Street EPS estimates by 8 cents per share. >>5 Rocket Stocks to Buy This Week From a technical perspective, SUPN ripped higher here right above some near-term support at $4.85 with heavy upside volume. This move is quickly pushing shares of SUPN within range of triggering a major breakout trade. That trade will hit if SUPN manages to take out its 50-day at $5.64 and then once it clears more near-term resistance levels at $5.68 to $6.29 with high volume. Traders should now look for long-biased trades in SUPN as long as it's trending above some key near-term support levels at $5 or $4.85 and then once it sustains a move or close above those breakout levels with volume that hits near or above 381,992 shares. If that breakout triggers soon, then SUPN will set up to re-test or possibly take out its next major overhead resistance levels at $7 to $8. BG MedicineBG Medicine ( BGMD) is a life sciences company focused on the discovery, development and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare. This stock closed up 3.5% to $1.73 on Tuesday. Tuesday's Range: $1.65-$1.76 52-Week Range: $1.00-$7.10 Volume: 154,000 Three-Month Average Volume: 255,357 From a technical perspective, BGMD trended up here right above some near-term support levels at $1.60 to $1.56 with lighter-than-average volume. This stock has been trending sideways for the last month and change, with shares moving between $1.56 on the downside and around $2 on the upside. Shares of BGMD are now quickly moving within range of triggering a near-term breakout trade above the upper-end of its recent sideways trading chart pattern. That breakout will hit if BGMD manages to take out its 50-day at $1.76 and then once it clears more resistance levels at $1.84 to $2 with high volume.
Sunshine Heart (SSH) plunges after the company, known for its C-Pulse Heart Assist System to treat moderate to severe heart failure, reported a fourth-quarter loss per share that was wider than analysts' expectations and also provided a discouraging update on a pivotal trial. The company noted a loss of 42 cents a share, wider than the consensus estimate of 40 cents a share. Sunshine Heart reported no revenue, as expected. Sunshine Heart also provided an update on its pivotal C-Pulse® COUNTER HF U.S. investigational study and noted the activation of eight sites with a total of 24 additional sites committed to participate, which increases the total number to 32. The company reported in January 2014 that one additional patient had enrolled in the trial for a total of three patients through year-end. Unfortunately, the pace of enrollment in the trials has been extremely slow. The trial, which would have an estimated enrollment of 388, began in Nov. 2012 and has an estimated data collection date of April 2016 and an estimated study completion date of April 2017.